Mirtavoos-Mahyari Hanifeh, Ghafouri-Fard Soudeh, Khosravi Adnan, Motevaseli Elahe, Esfahani-Monfared Zahra, Seifi Sharareh, Salimi Babak, Oskooei Vahid Kholghi, Ghadami Mohsen, Modarressi Mohammad Hossein
Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Transl Med. 2019 Apr 18;8(1):14. doi: 10.1186/s40169-019-0229-6.
Plasma circulating cell-free (cf) DNA is regarded as a source of tumor DNA. Based on availability of blood tissue for the purposes of early detection of cancer and patients' follow-up, several studies have evaluated concentration of cf DNA in cancer patients in association with tumor features. In the present study, we assessed concentration of cf DNA in lung cancer patients with two commercial kits (MN and QIAGEN) to find whether it can be used as a prognostic biomarker.
Primary cf DNA concentrations as measured by QIAGEN kit was significantly higher in patients who died in the follow-up period compared with alive patients (P = 0.007). Moreover, the concentrations as measured by both methods were higher in patients who experienced recurrence in the follow-up period compared with patients without recurrence (P = 0.008 and 0.007 for MN and QIAGEN kits respectively). Significant associations were also found between cf DNA concentrations and tumor stage (P = 0.005 and 0.02 for MN and QIAGEN kits respectively). Notably, cf DNA concentration was higher in metastatic tumors compared with non-metastatic tumors in association with number of involved organs. Based on the AUC values, both kits could differentiate metastatic cancers from non-metastatic ones with accuracy of 98%.
The current study highlights the accuracy of cf DNA concentrations for prediction of disease course in lung cancer patients.
血浆循环游离（cf）DNA被视为肿瘤DNA的来源。基于血液组织可用于癌症早期检测和患者随访的目的，多项研究评估了癌症患者中cf DNA的浓度及其与肿瘤特征的关系。在本研究中，我们使用两种商业试剂盒（MN和QIAGEN）评估了肺癌患者中cf DNA的浓度，以确定其是否可作为一种预后生物标志物。
与存活患者相比，随访期间死亡患者使用QIAGEN试剂盒测得的原发性cf DNA浓度显著更高（P = 0.007）。此外，与无复发患者相比，随访期间出现复发的患者使用两种方法测得的浓度均更高（MN和QIAGEN试剂盒分别为P = 0.008和0.007）。cf DNA浓度与肿瘤分期之间也存在显著关联（MN和QIAGEN试剂盒分别为P = 0.005和0.02）。值得注意的是，与非转移性肿瘤相比，转移性肿瘤中的cf DNA浓度更高，且与受累器官数量有关。基于AUC值，两种试剂盒均可将转移性癌症与非转移性癌症区分开来，准确率达98%。
本研究突出了cf DNA浓度在预测肺癌患者病程方面的准确性。
Zotero 插件
